Catalent has signed an agreement with Cybin to apply Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for the delivery of Cybin’s novel deuterated tryptamine (CYB003), a potential therapy for treatment-resistant psychiatric disorders.
Zydis technology creates a freeze-dried tablet that disperses almost instantly in the mouth without water. Delivering CYB003 in such a dose form could have significant benefits, as an ODT would allow pre-gastric delivery and prevent first pass metabolism, potentially improving the pharmacokinetic profile of the drug. The project is due to commence in April 2021 and will involve initial feasibility studies being conducted for the manufacturing and analytical testing of ODT doses containing varying quantities of CYB003, alongside different excipients.
“We look forward to working with Cybin to potentially develop a novel and fast-acting therapy for treatment-resistant psychiatric disorders. The Zydis platform is an ideal technology to leverage for this type of drug formulation, as pre-gastric absorption is crucial for efficacy,” Jonathan Arnold, President of Oral and Specialty Delivery at Catalent, said.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“We are excited to partner with the team at Catalent with the aim of developing fast-acting, shorter-duration formulations of CYB003, recently acquired as part of our acquisition of Adelia Therapeutics. Our focus on reducing the need for health system resources, such as in-clinic therapist time, is an important part of our goal to create scalable, more accessible treatments for mental health disorders,” Doug Drysdale, Cybin’s CEO, said.